A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections

BACKGROUND: Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. METHODS: This was...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Hart, Delaney E, Gallagher, Jason C, Puzniak, Laura A, Hirsch, Elizabeth B
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Major Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7990512/
https://ncbi.nlm.nih.gov/pubmed/33796600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofab089
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars